

THRU ONLINE FILING

June 15, 2017

BSE Limited
Phiroze Jeejeebhoy Towers
27th Floor, Dalal Street
Mumbai 400 023

Dear Sir,


**Sub: US FDA Update on Company's Formulations manufacturing units situated at
SEZ Indore (Pithampur) and Piparia (Silvassa)**

Further to our letters dated March 25, 2015 and February 1, 2016, we now wish to inform you that the Company has now received a communication from USFDA stating that all the drugs manufactured from the Company's aforesaid manufacturing facilities will be henceforth refused admission into the United States (without any exception) until the Company can demonstrate that the drugs manufactured from these manufacturing sites and intended for the US market are in compliance with cGMP.

Kindly make note of the same.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary

Cc: The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Flr, Plot # C/1
G Block, Bandra-Kurla Complex,
Bandra (E), Mumbai 400 051.

Ipca Laboratories Ltd.
www.ipca.com